Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202097 | 0.82 | TLR7 (0.42) | ACHE | |
| SCHEMBL202179 | 0.80 | KDM4E (0.35) | PIK3CDPIK3CAPIK3CGMTOR | |
| SCHEMBL202353 | 0.79 | TLR7 (0.41) | — | |
| SCHEMBL202499 | 0.74 | TLR7 (0.44) | — | |
| SCHEMBL12165325 | 0.72 | PIK3CD (0.42) | PRMT5HRH4PIK3CDPIK3CAPIK3CG | |
| SCHEMBL1775272 | 0.68 | PRMT5 (0.37) | PRMT5HRH4PIK3CDPIK3CAPIK3CG | |
| SCHEMBL10123111 | 0.66 | PRMT5 (0.50) | PRMT5HRH4 | |
| SCHEMBL202424 | 0.66 | KDM4E (0.38) | ACHE | |
| SCHEMBL4299811 | 0.65 | TLR7 (0.42) | PRMT5HRH4PIK3CDPIK3CAPIK3CG | |
| SCHEMBL1774015 | 0.65 | PRMT5 (0.35) | PRMT5HRH4PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | PRMT5 959/4885HRH4 94/4885PIK3CD 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.